HC Wainwright Issues Pessimistic Forecast for ADC Therapeutics (NYSE:ADCT) Stock Price

ADC Therapeutics (NYSE:ADCT) had its price objective lowered by equities researchers at HC Wainwright from $8.00 to $7.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 71.99% from the stock’s previous close. HC Wainwright also issued estimates for ADC Therapeutics’ Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.37) EPS.

A number of other research analysts also recently commented on ADCT. Wall Street Zen downgraded ADC Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a report on Wednesday, October 8th. Guggenheim reissued a “buy” rating and issued a $10.00 price target on shares of ADC Therapeutics in a report on Wednesday, August 13th. Finally, Royal Bank Of Canada raised ADC Therapeutics from an “outperform” rating to a “moderate buy” rating and reduced their price target for the company from $8.00 to $5.00 in a report on Friday, June 20th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, ADC Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

ADC Therapeutics Stock Performance

ADCT stock opened at $4.07 on Thursday. ADC Therapeutics has a 1 year low of $1.05 and a 1 year high of $4.74. The firm has a market cap of $457.88 million, a P/E ratio of -2.59 and a beta of 1.99. The stock has a 50-day simple moving average of $3.55 and a 200-day simple moving average of $2.77.

ADC Therapeutics (NYSE:ADCT) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). The company had revenue of $18.84 million during the quarter, compared to analysts’ expectations of $17.82 million. On average, equities research analysts predict that ADC Therapeutics will post -1.69 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ADCT. Cerity Partners LLC bought a new position in ADC Therapeutics during the 1st quarter worth approximately $25,000. Atria Wealth Solutions Inc. acquired a new stake in shares of ADC Therapeutics during the 1st quarter worth approximately $28,000. Invesco Ltd. raised its position in shares of ADC Therapeutics by 286.1% during the 1st quarter. Invesco Ltd. now owns 132,704 shares of the company’s stock worth $187,000 after purchasing an additional 98,335 shares during the period. Nuveen LLC acquired a new stake in shares of ADC Therapeutics during the 1st quarter worth approximately $214,000. Finally, Russell Investments Group Ltd. raised its position in shares of ADC Therapeutics by 136.3% during the 1st quarter. Russell Investments Group Ltd. now owns 39,688 shares of the company’s stock worth $56,000 after purchasing an additional 22,894 shares during the period. Institutional investors own 41.10% of the company’s stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.